Home > Boards > US Listed > Medical - Equipment > Cytosorbents Corporation (CTSO)

REMOVE-Results ?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Aliberto Member Profile
 
Followed By 1
Posts 172
Boards Moderated 0
Alias Born 03/15/17
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/24/2022 4:31:32 PM
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology PR Newswire (US) - 1/24/2022 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/20/2022 4:32:05 PM
Leerink Partners Thinks Cytosorbents’ Stock is Going to Recover TipRanks - 1/20/2022 3:46:07 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/18/2022 4:32:30 PM
CytoSorbents jumps 1.86% on prelim FY21 and Q4 revenue above the consensus Seeking Alpha - 1/18/2022 7:35:44 AM
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue PR Newswire (US) - 1/18/2022 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/7/2022 5:11:35 PM
Dawson James Remains a Buy on Cytosorbents (CTSO) TipRanks - 1/5/2022 4:10:04 AM
Dawson James Sticks to Their Buy Rating for Cytosorbents (CTSO) TipRanks - 1/5/2022 4:08:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/30/2021 5:29:04 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/30/2021 5:27:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/21/2021 9:01:13 AM
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular PR Newswire (US) - 12/21/2021 7:05:00 AM
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) PR Newswire (US) - 12/20/2021 7:10:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/13/2021 5:01:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/13/2021 9:06:01 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 6:11:44 PM
CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference PR Newswire (US) - 11/15/2021 4:30:00 PM
Cytosorbents EPS misses by $0.03, beats on revenue Seeking Alpha - 11/4/2021 4:29:11 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2021 4:15:41 PM
CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results PR Newswire (US) - 11/4/2021 4:15:00 PM
Cytosorbents Q3 2021 Earnings Preview Seeking Alpha - 11/3/2021 5:35:41 PM
CytoSorbents Comments on REMOVE Study Presentation PR Newswire (US) - 10/20/2021 7:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2021 6:26:17 AM
Aliberto   Monday, 03/01/21 05:11:41 AM
Re: clints post# 25985
Post # of 27014 
REMOVE-Results ?

- regarding REMOVE results, after this very current publication (publication date Feb.03.2021) from Switzerland, I am absolutely no longer sure

Hemoadsorption during Cardiopulmonary Bypass in Patients with Endocarditis Undergoing Valve Surgery

- ... maybe this is why the publication of the REMOVE results will be "postponed" and the head of studies and CTSO management is now desperately looking for any positive data in the results


COVID-use ?

- can it be used at all for Corona in Germany due to the new "Recommendations (= guidelines !) for inpatient therapy for patients with COVID-19" at the ICU?
(See point 7.1 "Hospitalized patients with COVID-19 should receive standard drug thromboembolism prophylaxis with low molecular weight heparin in the absence of contraindications. Fondaparinux can be used as an alternative.")

S3-guideline - recommendations for inpatient therapy for patients with COVID-19



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences